HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.05761207v1 3/4/1034    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Ishii, H. Articles by Murohara, T. PubMed PubMed Citation Articles by Ishii, H. Articles by Murohara, T.

Cilostazol Improves Long-Term Patency after Percutaneous Transluminal Angioplasty in Hemodialysis Patients with Peripheral Artery Disease

Hideki Ishii^*,, Yoshitake Kumada, Takanobu Toriyama, Toru Aoyama, Hiroshi Takahashi, Shigeki Yamada, Yoshinari Yasuda, Yukio Yuzawa, Shoichi Maruyama, Seiichi Matsuo, Tatsuaki Matsubara, and Toyoaki Murohara^*

^* Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan, Cardiolovascular Center, Nagoya Kyoritsu Hospital, Nagoya, Japan, Department of Clinical Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan, and Department of Internal Medicine, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan

Correspondence: Hideki Ishii, Department of Cardiology, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. Phone: +81-52-744-2147; Fax: +81–52-744–2157; E-mail: hkishii{at}med.nagoya-u.ac.jp

Background and objectives: Peripheral artery disease (PAD) is common in patients on hemodialysis (HD). Recently, cilostazol has been reported to reduce target lesion revascularization (TLR) after percutaneous transluminal angioplasty (PTA) for PAD in the general population. This study aimed to clarify the effects of cilostazol administration on long-term patency after PTA in HD patients.

Design, setting, participants, & measurements: Three-hundred seventy-two consecutive lesions in 193 HD patients successfully undergoing PTA were enrolled in the study and divided into two groups: patients receiving 100 mg cilostazol twice daily in conjunction with standard therapy (130 lesions in 71 patients) and those not administered cilostazol (242 lesions in 122 patients). Effects of cilostazol on preventing restenosis after PTA in these patients were investigated.

Results: Kaplan-Meier analysis demonstrated the 5-yr patency rate was significantly higher in the cilostazol group than in the control group [52.4 versus 32.9%, hazard ratio (HR) 0.55; 95% confidence interval (CI) 0.39 to 0.77, P = 0.0005]. Cox multivariate analysis revealed that administration of cilostazol was an independent predictor of preventing restenosis (HR 0.56, 95% CI 0.36 to 0.87, P = 0.010). In 102 lesions matched after propensity score analysis, cilostazol had a beneficial effect on preventing restenosis (58.4 versus 34.7%, HR 0.47, 95% CI 0.30 to 0.75, P = 0.0017) and was an independent predictor of preventing restenosis (HR 0.50; 95% CI 0.26 to 0.87, P = 0.014) after multivariate Cox analysis.

Conclusions: Cilostazol administration improves long-term patency after PTA in HD patients with PAD.